Guggenheim lowered the firm’s price target on Veracyte (VCYT) to $37 from $45 and keeps a Buy rating on the shares. The firm adjusted its 2025 revenue and test volumes based on recent management commentary, updated its model for the latest 10K release post-earnings and revised its price target to reflect multiple compression in the peer group.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT: